查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1581204

鎦177 市場：按形式、給藥途徑、最終用戶、應用分類 - 2025-2030 年全球預測

Lutetium-177 Market by Form (Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177), Route of Administration (Intravenous, Oral), End User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年鎦177市值為1.677億美元，預計2024年將達到2.0256億美元，複合年成長率為21.44%，到2030年將達到6.5353億美元。

鎦-177 是一種放射性同位素，主要用於治療神經內分泌腫瘤和某些攝護腺癌。對鎦177 的需求源於其能夠提供靶向輻射，同時對周圍健康組織的損害最小，從而在腫瘤學中提供治療益處。其應用包括專門從事癌症治療的醫療中心、放射性藥物製造商以及探索先進癌症治療的研究機構。主要最終用途是醫院、專科診所和診斷中心。影響鎦-177市場的主要成長要素包括癌症發生率上升、放射性藥物技術的進步以及政府對癌症研究的資助增加。最近的創新重點是最佳化鎦-177的生產和提高聯合治療中輸送系統的有效性，為相關人員提供有利的機會。企業應透過投資研究合作、擴大生產設施以及尋求監管部門核准來開拓開拓的市場來抓住機會。

主要市場統計
基準年[2023] 1.677 億美元
預測年份 [2024] 20256萬美元
預測年份 [2030] 65353萬美元
複合年成長率（%） 21.44%

然而，鎦177 市場面臨製造成本高、監管要求嚴格以及製造過程必需的原料供應有限等挑戰。此外，放射性藥物的處理和管理需要專門的基礎設施和技術人員，這限制了其廣泛使用。為了克服這些障礙，技術創新可以專注於透過新穎的合成技術來提高生產效率，並加強供應鏈機制以確保原料的可用性。潛在的研究領域包括開發下一代放射性標記化合物和探索針對患者特異性治療的個人化醫學方法。

該市場的特點是技術快速進步和競爭動態，需要持續的策略創新才能保持競爭力。該市場為與學術研究機構建立夥伴關係以促進產品開發和創新提供了肥沃的土壤。透過利用這些見解，市場相關人員可以駕馭監管環境，採用新技術，並優先考慮生產的永續性，以確保在不斷發展的癌症藥物領域佔據長期地位，確保成功和市場領導地位。

市場動態：揭示快速發展的鎦177 市場的關鍵市場洞察

供需的動態交互作用正在改變鎦177 市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 在癌症治療中擴大採用標靶核素治療
    • 由於神經內分泌腫瘤盛行率不斷增加，需要先進的治療
  • 市場限制因素
    • 複雜的鎦生產與供應鏈物流- 177
  • 市場機會
    • 放射性藥物和成像技術的重大創新
    • 政府對核子醫學研究的資助與支持
  • 市場挑戰
    • 鎦-177 監管和合規障礙及可用性限制

波特五力戰略工具駕馭鎦177 市場

波特五力架構是了解鎦-177 市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解鎦177 市場的外部影響

外部宏觀環境因素在塑造鎦177市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解鎦177 市場的競爭狀況

鎦177 市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣鎦177 市場供應商績效評估

FPNV定位矩陣是評估鎦177市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃鎦177 市場的成功之路

對於想要加強在全球市場的影響力的公司來說，對鎦177 市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 在癌症治療中擴大採用標靶放射性核素療法
      • 神經內分泌腫瘤盛行率的增加需要先進的治療方法
    • 抑制因素
      • 複雜的鎦生產與供應鏈物流- 177
    • 機會
      • 放射性藥物和影像技術的重大創新
      • 政府對核子醫學研究的資助與支持
    • 任務
      • 鎦-177 監管和合規障礙限制了可用性
  • 市場區隔分析
    • 形式：擴大使用非載體添加的鎦177，由於其高純度，最大限度地減少副作用
    • 應用：鎦-177在癌症治療中的使用正在迅速增加，提供更強化的治療效果
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章鎦177 市場：依形式

  • 營運商添加鎦- 177
  • 未添加載體鎦177

第 7 章鎦177 市場：按管理途徑

  • 靜脈
  • 口服

第 8 章鎦177 市場：依最終用戶分類

  • 診斷中心
  • 醫院
  • 專業癌症治療中心

第 9 章鎦177 市場：依應用分類

  • 癌症治療
    • 神經內分泌腫瘤
    • 攝護腺癌
  • 非癌症治療

第10章鎦177美洲市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區鎦177市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章鎦177歐洲、中東和非洲市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • SHINE Technologies 與 Blue Earth Therapeutics 合作治療攝護腺癌
    • Nuclearelectrica 和法馬通合作開發鎦-177 用於標靶癌症治療，
    • Nucleus Radiopharma 與 SHINE Technologies 簽署高純度鎦-177 協議，以推進癌症治療
    • SHINE Technologies 在北美開設 Lu-177 生產設施，大幅提升癌症治療能力
  • 戰略分析和建議

公司名單

  • Actinium Pharmaceuticals, Inc.
  • Bayer AG
  • BWX Technologies, Inc.
  • Cardinal Health, Inc.
  • Curium Pharma
  • Eckert & Ziegler Radiopharma GmbH
  • Framatome
  • Fusion Pharmaceuticals Inc. by AstraZeneca
  • IBA Radiopharma Solutions
  • Isotopia Ltd.
  • ITM Isotope Technologies Munich SE
  • Lantheus Holdings, Inc.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • NTP Radioisotopes SOC Ltd.
  • Nuclear Research and Consultancy Group
  • PerkinElmer, Inc.
  • RadioMedix, Inc.
  • RayzeBio, Inc. by Bristol Myers Squibb
  • SHINE Technologies, LLC
  • Telix Pharmaceuticals Limited.
Product Code: MRR-9A6A6F2977DA

The Lutetium-177 Market was valued at USD 167.70 million in 2023, expected to reach USD 202.56 million in 2024, and is projected to grow at a CAGR of 21.44%, to USD 653.53 million by 2030.

Lutetium-177 is a radioisotope utilized primarily in targeted radionuclide therapy, notably in treating neuroendocrine tumors and certain prostate cancers. The necessity of Lutetium-177 arises from its ability to deliver targeted radiation with minimal damage to surrounding healthy tissues, offering a therapeutic advantage in oncology. Its application scopes cover medical centers specializing in oncology treatments, radiopharmaceutical manufacturers, and research institutions exploring advanced cancer therapies. The end-use predominantly spans hospitals, specialty clinics, and diagnostic centers. Key growth factors influencing the Lutetium-177 market include rising cancer prevalence, advancements in radiopharmaceutical technologies, and increased government funding for cancer research. Recent innovations focus on optimizing Lutetium-177 production and enhancing the efficacy of delivery systems in combination therapies, offering lucrative opportunities for stakeholders. Companies should seize opportunities by investing in research collaborations, expanding production facilities, and seeking regulatory approvals to harness untapped markets.

KEY MARKET STATISTICS
Base Year [2023] USD 167.70 million
Estimated Year [2024] USD 202.56 million
Forecast Year [2030] USD 653.53 million
CAGR (%) 21.44%

However, the Lutetium-177 market faces challenges such as high production costs, stringent regulatory requirements, and limited availability of raw materials elemental to the production process. Furthermore, the necessity for specialized infrastructure and skilled personnel for handling and administering radiopharmaceuticals limits widespread adoption. To overcome these barriers, innovation can focus on improving production efficiency through novel synthesis techniques and enhancing supply chain mechanisms to ensure material availability. Potential research areas include developing next-generation radiolabeled compounds and exploring personalized medicine approaches to patient-specific therapies.

The market is characterized by rapid technological advancements and competitive dynamics, requiring continuous strategic innovation to maintain a competitive edge. It presents a fertile ground for developing partnerships with academic and research institutions to fuel product development and innovation. In leveraging these insights, market players should navigate the regulatory landscape adeptly, adopt emerging technologies, and prioritize sustainability in production to ensure long-term success and market leadership in the evolving landscape of cancer therapeutics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lutetium-177 Market

The Lutetium-177 Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of targeted radionuclide therapy for cancer treatment
    • Rising prevalence of neuroendocrine tumors necessitates advanced therapies
  • Market Restraints
    • Complex production and supply chain logistics of lutetium-177
  • Market Opportunities
    • Significant innovations in radiopharmaceuticals and imaging technologies
    • Government funding and support for nuclear medicine research
  • Market Challenges
    • Limited availability with regulatory and compliance barriers for lutetium-177

Porter's Five Forces: A Strategic Tool for Navigating the Lutetium-177 Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lutetium-177 Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lutetium-177 Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lutetium-177 Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lutetium-177 Market

A detailed market share analysis in the Lutetium-177 Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lutetium-177 Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lutetium-177 Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lutetium-177 Market

A strategic analysis of the Lutetium-177 Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lutetium-177 Market, highlighting leading vendors and their innovative profiles. These include Actinium Pharmaceuticals, Inc., Bayer AG, BWX Technologies, Inc., Cardinal Health, Inc., Curium Pharma, Eckert & Ziegler Radiopharma GmbH, Framatome, Fusion Pharmaceuticals Inc. by AstraZeneca, IBA Radiopharma Solutions, Isotopia Ltd., ITM Isotope Technologies Munich SE, Lantheus Holdings, Inc., NorthStar Medical Radioisotopes, LLC, Novartis AG, NTP Radioisotopes SOC Ltd., Nuclear Research and Consultancy Group, PerkinElmer, Inc., RadioMedix, Inc., RayzeBio, Inc. by Bristol Myers Squibb, SHINE Technologies, LLC, and Telix Pharmaceuticals Limited..

Market Segmentation & Coverage

This research report categorizes the Lutetium-177 Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Form, market is studied across Carrier Added Lutetium-177 and Non-Carrier-Added Lutetium-177.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on End User, market is studied across Diagnostic Centers, Hospitals, and Specialized Cancer Treatment Centers.
  • Based on Application, market is studied across Cancer Treatment and Non-Cancer Treatment. The Cancer Treatment is further studied across Neuroendocrine Tumors and Prostate Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of targeted radionuclide therapy for cancer treatment
      • 5.1.1.2. Rising prevalence of neuroendocrine tumors necessitates advanced therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Complex production and supply chain logistics of lutetium-177
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant innovations in radiopharmaceuticals and imaging technologies
      • 5.1.3.2. Government funding and support for nuclear medicine research
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability with regulatory and compliance barriers for lutetium-177
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Form: Proliferating usage of the non-carrier-added lutetium-177 minimizing side effects due to its high purity
    • 5.2.2. Application: Burgeoning utilization of lutetium-177 in cancer treatment provides more focused therapeutic impact
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lutetium-177 Market, by Form

  • 6.1. Introduction
  • 6.2. Carrier Added Lutetium-177
  • 6.3. Non-Carrier-Added Lutetium-177

7. Lutetium-177 Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral

8. Lutetium-177 Market, by End User

  • 8.1. Introduction
  • 8.2. Diagnostic Centers
  • 8.3. Hospitals
  • 8.4. Specialized Cancer Treatment Centers

9. Lutetium-177 Market, by Application

  • 9.1. Introduction
  • 9.2. Cancer Treatment
    • 9.2.1. Neuroendocrine Tumors
    • 9.2.2. Prostate Cancer
  • 9.3. Non-Cancer Treatment

10. Americas Lutetium-177 Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Lutetium-177 Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Lutetium-177 Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. SHINE Technologies partners with Blue Earth Therapeutics for prostate cancer
    • 13.3.2. Nuclearelectrica and Framatome partnered to produce Lutetium-177 for targeted cancer treatments,
    • 13.3.3. Nucleus Radiopharma and SHINE Technologies deal for high-purity Lutetium-177 to boost cancer treatment
    • 13.3.4. SHINE Technologies opens Lu-177 production facility in North America, significantly boosting capacity for cancer treatments
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Actinium Pharmaceuticals, Inc.
  • 2. Bayer AG
  • 3. BWX Technologies, Inc.
  • 4. Cardinal Health, Inc.
  • 5. Curium Pharma
  • 6. Eckert & Ziegler Radiopharma GmbH
  • 7. Framatome
  • 8. Fusion Pharmaceuticals Inc. by AstraZeneca
  • 9. IBA Radiopharma Solutions
  • 10. Isotopia Ltd.
  • 11. ITM Isotope Technologies Munich SE
  • 12. Lantheus Holdings, Inc.
  • 13. NorthStar Medical Radioisotopes, LLC
  • 14. Novartis AG
  • 15. NTP Radioisotopes SOC Ltd.
  • 16. Nuclear Research and Consultancy Group
  • 17. PerkinElmer, Inc.
  • 18. RadioMedix, Inc.
  • 19. RayzeBio, Inc. by Bristol Myers Squibb
  • 20. SHINE Technologies, LLC
  • 21. Telix Pharmaceuticals Limited.

LIST OF FIGURES

  • FIGURE 1. LUTETIUM-177 MARKET RESEARCH PROCESS
  • FIGURE 2. LUTETIUM-177 MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LUTETIUM-177 MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LUTETIUM-177 MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LUTETIUM-177 MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LUTETIUM-177 MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LUTETIUM-177 MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LUTETIUM-177 MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES LUTETIUM-177 MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES LUTETIUM-177 MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. LUTETIUM-177 MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. LUTETIUM-177 MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LUTETIUM-177 MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LUTETIUM-177 MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LUTETIUM-177 MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LUTETIUM-177 MARKET DYNAMICS
  • TABLE 7. GLOBAL LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LUTETIUM-177 MARKET SIZE, BY CARRIER ADDED LUTETIUM-177, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LUTETIUM-177 MARKET SIZE, BY NON-CARRIER-ADDED LUTETIUM-177, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LUTETIUM-177 MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LUTETIUM-177 MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LUTETIUM-177 MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LUTETIUM-177 MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LUTETIUM-177 MARKET SIZE, BY SPECIALIZED CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LUTETIUM-177 MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LUTETIUM-177 MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LUTETIUM-177 MARKET SIZE, BY NON-CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES LUTETIUM-177 MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM LUTETIUM-177 MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM LUTETIUM-177 MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM LUTETIUM-177 MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM LUTETIUM-177 MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM LUTETIUM-177 MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. LUTETIUM-177 MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 233. LUTETIUM-177 MARKET, FPNV POSITIONING MATRIX, 2023